TOP
STORY

Scientists established enzalutamide resistant-prostate cancer cell lines and examined the long noncoding RNA Malat1 (Malat1) function in conferring enzalutamide resistance. They also examined the in vivo effects of Malat1 short interfering RNA and the AR-v7 degradation enhancer, ASC-J9®. [Eur Urol]
Full Article

LABORATORY RESEARCH

Researchers found that castration-resistant prostate cancer cells showed increased expression of a set of homologous recombination-associated genes, including BRCA1, RAD54L, and RMI2. [Sci Signal]
Abstract

To determine whether androgen receptor (AR) variants play a role in bicalutamide resistance, scientists developed bicalutamide resistant LNCaP cells and found that these resistant cells express significantly increased levels of AR variants, particularly AR-V7, both at the mRNA and protein levels. [Mol Cancer Ther]
Abstract

Scientists investigated the role of endonuclease domain containing 1 (ENDOD1) in prostate cancer (PCa). Real-time PCR and western blot were used to detect ENDOD1 mRNA and protein expression in normal prostatic epithelial and PCa cell lines. [BMC Cancer]
Full Article

The authors provide significant insight and advances in the theranostic role of magnetic nanoparticles through the documentation of unique magnetic nanoparticles used in prostate cancer, their interaction with prostate cancer cells, in vivo fate, targeting, and biodistribution. [Drug Discov Today]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

Sophiris Bio Inc. reported that it has received the regulatory clearance for the diluent – the medium in which topsalysin is diluted. Clinical sites can now begin dosing eligible patients in a Phase IIb study in localized prostate cancer. [Sophiris Bio Inc.]
Press Release

Churchill Pharmaceuticals, LLC., announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for YONSA™, an improved ultramicrosize formulation of abiraterone acetate. YONSA is a CYP17 inhibitor for the treatment of metastatic castration-resistant prostate cancer in combination with methylprednisolone. [Churchill Pharmaceuticals, LLC.]
Press Release

ORYX announced positive findings from 16 patients treated with the oncolytic virus, ParvOryx, in combination with Avastin® and with immune checkpoint inhibitors Keytruda® or Opdivo® under compassionate use programs. [ORYX]
Press Release

Donald Trump planned to include an 11% cut to National Science Foundation’s (NSF)’s $7.4 billion budget in his first full spending request to Congress. The news—which was publicly unveiled as part of the president’s $4.1 trillion budget for 2018—sent Jim Olds, who leads the biology directorate at the NSF, and the heads of NSF’s other six research and education programs scrambling to erase big chunks of their portfolios without sacrificing NSF’s ability to fund the best new ideas. [ScienceInsider]
Editorial

A Colombian biologist who faced a criminal trial for posting another scientist’s thesis online has been cleared of copyright violation — an offense that, under Colombian law, might have brought him a jail sentence. [Nature News]
Editorial

The US Food and Drug Administration has issued its first approval of a cancer drug that targets tumors with specific mutations, regardless of where in the body the tumor first took root. [Nature News]
Editorial

Police in the northwestern region of Xinjiang, China, have been collecting DNA samples from citizens and are now ramping up their capacity to analyze that genetic cache, according to evidence compiled by activists and details gathered by Nature. [Nature News]
Editorial